These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37491721)

  • 1. Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet's disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study.
    Lee SB; Hong HS; Lee CK; Lee BI; Kim S; Koh SJ; Yu H; Park JB; Hwang SW; Ye BD; Yang SK; Park SH;
    Korean J Intern Med; 2023 Sep; 38(5):661-671. PubMed ID: 37491721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.
    Yu J; Shin SJ; Park YJ; Kim HW; Lee BI; Ye BD; Kim GT; Kim SK; Kim JS; Kim YH; Jeong S; Cheon JH
    BMC Gastroenterol; 2023 Dec; 23(1):449. PubMed ID: 38114956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.
    Vitale A; Emmi G; Lopalco G; Gentileschi S; Silvestri E; Fabiani C; Urban ML; Frediani B; Galeazzi M; Iannone F; Rigante D; Cantarini L
    Clin Rheumatol; 2017 Feb; 36(2):451-455. PubMed ID: 27679471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
    Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
    Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
    Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.
    Martín-Varillas JL; Calvo-Río V; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Garfella MH; Pascual EV; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; Salom D; Ortego N; García-Serrano JL; Callejas-Rubio JL; Herreras JM; García-Aparicio Á; Maíz O; Blanco A; Torre I; Díaz-Valle D; Pato E; Aurrecoechea E; Caracuel MA; Gamero F; Minguez E; Carrasco-Cubero C; Olive A; Vázquez J; Ruiz-Moreno O; Manero J; Muñoz-Fernández S; Martinez MG; Rubio-Romero E; Toyos-Sáenz de Miera FJ; López Longo FJ; Nolla JM; Revenga M; González-Vela C; Loricera J; Atienza-Mateo B; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
    Ophthalmology; 2018 Sep; 125(9):1444-1451. PubMed ID: 29602570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
    Miyagawa I; Nakano K; Iwata S; Nakayamada S; Saito K; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Tanaka Y
    Arthritis Res Ther; 2019 Jun; 21(1):151. PubMed ID: 31228955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.
    Chung SH; Park SJ; Hong SP; Cheon JH; Kim TI; Kim WH
    World J Gastroenterol; 2013 Aug; 19(32):5389-92. PubMed ID: 23983446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease.
    Jung YS; Kim SW; Yoon JY; Lee JH; Jeon SM; Hong SP; Kim TI; Kim WH; Cheon JH
    Inflamm Bowel Dis; 2011 Oct; 17(10):2130-7. PubMed ID: 21910175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib for the treatment of intestinal Behçet's disease: A pilot study.
    Liu J; Yu X; Wang Z; Liu W; Liu X; Wang X; Zhang M; Zhao Y; Zhang F; Yang H; Zheng W
    Clin Immunol; 2023 Feb; 247():109241. PubMed ID: 36702180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study.
    Park JB; Han SJ; Lee SB; Kim DH; Cheon JH; Hwang SW; Ye BD; Yang SK; Park SJ; Park SH;
    Yonsei Med J; 2024 May; 65(5):265-275. PubMed ID: 38653565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).
    Cheon JH; Kim HS; Han DS; Kim SK; Shin SJ; Kim JS; Ye BD; Song GA; Lee Y; Kim Y; Lee Y; Kim WH;
    Gut Liver; 2023 Sep; 17(5):777-785. PubMed ID: 36578194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
    Tanida S; Inoue N; Kobayashi K; Naganuma M; Hirai F; Iizuka B; Watanabe K; Mitsuyama K; Inoue T; Ishigatsubo Y; Suzuki Y; Nagahori M; Motoya S; Nakamura S; Arora V; Robinson AM; Thakkar RB; Hibi T
    Clin Gastroenterol Hepatol; 2015 May; 13(5):940-8.e3. PubMed ID: 25245624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of infliximab refractory intestinal Behçet's syndrome: A retrospective cohort study from the Shanghai Behçet's syndrome database.
    Bao HF; Hou CC; Ye B; Zou J; Luo D; Cai JF; Shen Y; Guan JL
    Mod Rheumatol; 2023 Jan; 33(1):207-216. PubMed ID: 34932796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
    Kinoshita H; Kunisaki R; Yamamoto H; Matsuda R; Sasaki T; Kimura H; Tanaka K; Naganuma M; Maeda S
    Intern Med; 2013; 52(17):1855-62. PubMed ID: 23994973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis.
    Yang S; Huang Z; Liu X; Li H; Xie L; Chen X; Wen F; Liang D; Su W
    Int Immunopharmacol; 2021 Apr; 93():107430. PubMed ID: 33581500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical outcomes of intestinal Behçet's disease: A 30-year cohort study at a tertiary hospital in South Korea.
    Park J; Park SJ; Park JJ; Kim TI; Cheon JH
    J Gastroenterol Hepatol; 2023 Mar; 38(3):386-392. PubMed ID: 36346041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term data on efficacy and safety of adalimumab in Behçet's disease.
    van der Houwen TB; Humer B; Missotten TO; Thiadens AAHJ; van Hagen PM; van Laar JAM
    Clin Immunol; 2023 Feb; 247():109242. PubMed ID: 36717068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.